Format

Send to:

Choose Destination

Links from PubMed

Items: 3

1.

Hiv

An infection caused by the human immunodeficiency virus. [from NCI]

MedGen UID:
5583
Concept ID:
C0019693
Disease or Syndrome
2.

Immunodeficiency

Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. [from NCI]

MedGen UID:
7034
Concept ID:
C0021051
Disease or Syndrome
3.

Maraviroc response

Maraviroc is used in combination with other antiretroviral agents to treat infection by human immunodeficiency virus type 1 (HIV-1), the virus that causes acquired immune deficiency syndrome (AIDS). Maraviroc is a chemokine receptor antagonist and works by blocking HIV-1 entry into cells. HIV-1 is classified according to which co-receptors it uses to gain entry in to the cell—either the chemokine receptor 5 (CCR5) or the CXC chemokine receptor 4 (CXCR4). These co-receptors are expressed on different types of cells, and HIV tropism refers to the types of cells and tissues that the virus infects and replicates in. A tropism assay is used to determine which co-receptor HIV-1 uses i.e., whether the virus is CCR5-tropic, CXCR4-tropic, or dual/mixed-tropic (dual refers to HIV-1 that is able to use both receptors, and mixed refers to a mixture of HIV-1 viruses, some of which use CCR5 and others that use CXCR4). Maraviroc is indicated for treatment of adults with CCR-5 tropic HIV-1 only and is not recommended for adults in whom CXCR4-tropic virus has been detected. The FDA states that tropism testing with a highly sensitive tropism assay is required for the appropriate use of maraviroc. [from NCBI]

MedGen UID:
450466
Concept ID:
CN077994
Sign or Symptom
Format

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center